Aspirin Management for Cardiac Catheterization
No, you should not hold aspirin before cardiac catheterization—aspirin must be continued and is a Class I recommendation from the ACC/AHA/SCAI guidelines. 1
Pre-Procedure Aspirin Management
For Patients Already on Aspirin
- Patients already taking daily aspirin therapy should take 81 mg to 325 mg before PCI. 1
- The 2011 ACC/AHA/SCAI guidelines give this a Class I recommendation with Level of Evidence B, meaning this is strongly supported by clinical trial data. 1
- Patients on chronic aspirin should continue their usual dose (75-325 mg) without interruption before the procedure. 2, 3
For Aspirin-Naive Patients
- Patients not on aspirin therapy should be given non-enteric aspirin 325 mg before PCI. 1
- Ideally, this loading dose should be administered at least 2 hours and preferably 24 hours before the procedure. 2, 3
Post-Procedure Aspirin Management
- After PCI, aspirin should be continued indefinitely (Class I recommendation, Level of Evidence A). 1
- The maintenance dose should be 81 mg daily, which is preferred over higher doses to minimize bleeding risk while maintaining antiplatelet efficacy. 1
Critical Rationale
The evidence strongly supports continuing aspirin because:
- Discontinuing aspirin increases the absolute risk of thrombotic events by approximately 2% within 30 days, including stroke recurrence and cardiovascular events. 4
- For patients with coronary stents, stopping aspirin dramatically increases the risk of catastrophic stent thrombosis, which carries higher mortality than any procedural bleeding risk. 5
- The thrombotic risk of aspirin discontinuation far outweighs the minimal and manageable bleeding risk during cardiac catheterization. 6
Dual Antiplatelet Therapy Considerations
If you're undergoing PCI with stent placement:
- A loading dose of a P2Y12 inhibitor (clopidogrel 600 mg, prasugrel, or ticagrelor 180 mg) should be given in addition to aspirin. 1
- Both aspirin and the P2Y12 inhibitor should be continued for at least 12 months after stent implantation for acute coronary syndrome patients. 1
- For non-ACS patients receiving drug-eluting stents, dual antiplatelet therapy should continue for at least 12 months if bleeding risk is not prohibitive. 1
Common Pitfalls to Avoid
- Never discontinue aspirin in patients with recent coronary stents (especially within 6-12 months for drug-eluting stents or 4-6 weeks for bare-metal stents), as stent thrombosis risk is maximal during these periods. 5
- Do not substitute aspirin with heparin or low-molecular-weight heparin bridging—anticoagulants do not protect against stent thrombosis and actually increase bleeding risk without providing adequate platelet inhibition. 5
- Avoid using enteric-coated aspirin for loading doses, as non-enteric formulations achieve faster and more reliable absorption. 1